CLYMClimb Bio Inc

1. Sep 3, 2026Climb Bio Announces CLYM116 Phase 1 Data Demonstrating Prolonged Half-Life and Best-In-Class APRIL Suppression Supporting Every-12-Week Dosing in IgA Nephropathy.Regulation FD disclosure · press release
2. Aug 14, 2026Climb Bio, Inc. Date: August 14, 2026 By: /s/ Aoife Brennan Aoife Brennan, M.B., Ch.B. President and Chief Executive Officer.Other event · Form 8-K
3. Aug 6, 2026Climb Bio Reports Second Quarter 2026 Financial Results and Provides Business Updates.Earnings release · press release
4. Jul 1, 2026Resignation of Director On June 29, 2026, Andrew Levin notified the board of directors (the “Board”) of Climb Bio, Inc. (the “Company”) of his resignation as a member of the Board, effective immediately.Director or officer change · Form 8-K
5. Jun 12, 2026On June 12, 2026, Climb Bio, Inc., a Delaware corporation (the “Company”), entered into an Open Market Sale Agreement℠ (the “Sales Agreement”) with Jefferies LLC, as agent (“Jefferies”), pursuant to which the Company may offer and sell shares of its common stock, $0.0001 par value per share (the “Common Stock”), from …Material agreement entered · Form 8-K
6. Jun 11, 2026On June 11, 2026, Climb Bio, Inc. (the “Company”) announced initial data from the ongoing Phase 1b portion of its Phase 1b/2a study evaluating budoprutug, an anti-CD19 monoclonal antibody, in adults with primary immune thrombocytopenia (“ITP”): • The Phase 1b portion of the Phase 1b/2a study (NCT07043946) is …Other event · Form 8-K
7. Jun 8, 2026At the 2026 Annual Meeting of Stockholders of Climb Bio, Inc. (the “Company”) held on June 5, 2026 (the “Annual Meeting”), the Company’s stockholders approved an amendment (the “2021 Plan Amendment”) to the Company’s 2021 Equity Incentive Plan (the “2021 Plan”) to amend the provision providing for an automatic share …Director or officer change · Form 8-K
8. Jun 5, 2026On June 5, 2026, Climb Bio, Inc. (the “Company”) announced translational pharmacometric modeling and initial Phase 1 safety data for CLYM116, its anti-APRIL monoclonal antibody: • A translational pharmacokinetic/pharmacodynamic model derived from pooled non-human primate (“NHP”) data projected healthy human exposure …Other event · Form 8-K
9. May 7, 2026Climb Bio Reports First Quarter 2026 Financial Results and Provides Business Updates.Earnings release · press release
10. May 5, 2026Broad B-Cell Mediated Disease Opportunity, and Upcoming Data Readouts.Regulation FD disclosure · press release
11. Apr 28, 2026Securities Purchase Agreement On April 27, 2026, Climb Bio, Inc., a Delaware corporation (the “Company”), entered into a securities purchase agreement (the “Securities Purchase Agreement”) with certain institutional accredited investors (the “Investors”), including an affiliate of RA Capital Management (“RA Capital”) …Material agreement entered · Form 8-K
12. Apr 3, 2026Departure of Senior Vice President, Finance On April 1, 2026, Climb Bio, Inc. (the “Company”) and Cindy Driscoll, its Senior Vice President, Finance and principal accounting officer, mutually agreed that Ms. Driscoll would separate from the Company, effective April 30, 2026 (the “Separation Date”)Director or officer change · Form 8-K

Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.